Floatz logo

RETEPLASE, RECOMBINANT

Stroke

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universityprotein_peptidePhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

140 Active assets in the Stroke cohort.

Asset / SponsorPhaseRating
Rivaroxaban
China National Center for Cardiovascular Diseases
Phase 4BBB
Tenecteplase
Assistance Publique - Hôpitaux de Paris
Phase 4BBB
Plavix
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BB
Lipitor
Duan Chuanzhi
Phase 4BB
WARFARIN
China National Center for Cardiovascular Diseases
Phase 4BB

View all 50 →

Same molecule, other indications

RETEPLASE, RECOMBINANT is also rated in:

Acute Ischemic StrokeDormant
B
Indicative ·
63 / 100
View asset →
Basilar Artery OcclusionDormant
B
Indicative ·
60 / 100
View asset →
stroke disorderDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →